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Abstract. Clinical Trials Corner of Journal of Huntington’s Disease will regularly review ongoing and recently completed
clinical trials in Huntington’s disease. In this inaugural issue, we list all currently registered and ongoing clinical trials, expand
on LEGATO-HD and IONIS-HTTRx, and cover two recently finished trials: Amaryllis and Pride-HD.
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INTRODUCTION
Clinical Trials Corner of Journal of Huntington’s
Disease is a new, regular, peer-reviewed section
devoted to highlighting ongoing or recently com-
pleted clinical trials in Huntington’s disease (HD).
To do so, we will gather and curate data from
the World Health Organization (WHO) International
Clinical Trials Search Portal (ICTRP)—a central
database that contains the trial registration datasets
provided by 17 clinical trial registries [1], includ-
ing the EU Clinical Trials Register (EU-CTR), the
USA ClinicalTrials.gov, among others—using the
keywords “Huntington’s” and “Huntington”. As trial
registration has been settled as a condition for pub-
lication by the International Committee of Medical
Journal Editors (ICMJE) since 2005 [2], and the
following year the WHO supported this measure,
this strategy is expected to harvest the majority of
ongoing clinical trials [3]. We will use only publicly
available information to describe the trials and their
results.
There are only two drugs specifically approved for
HD [4]: tetrabenazine [5] and deutetrabenazine [6],
both with a moderate effect on involuntary move-
∗Correspondence to: Edward J. Wild, UCL Huntington’s
Disease Centre, Russell Square 10–12, London, WC1B 5EH, UK.
E-mail: e.wild@ucl.ac.uk.
ments. No intervention has shown to modify disease
progression so far [7]. That being said, almost one
hundred clinical trials and 50 different interventions
have been or are currently being tested in HD [8]. It is
clear that modifying the progression of HD is excep-
tionally difficult; that success in preclinical models
so far has failed to anticipate the outcome of subse-
quent human trials; and that there is a need for not
only better drugs, but better means of deciding which
drugs we should test in patients.
In this inaugural Clinical Trials Corner, we will
list all currently registered and ongoing clinical
trials, expand on LEGATO-HD (NCT02215616)
and IONIS-HTTRx (NCT02519036), and cover two
recently finished trials: Amaryllis (NCT02197130)
and Pride-HD (NCT02006472). For future editions,
we will summarize current efforts and recent devel-
opments as well as providing in-depth information on
notable trials.
If you would like to draw attention to specific trials,
please feel free to email us at: f.rodrigues@ucl.ac.uk;
e.wild@ucl.ac.uk.
ONGOING CLINICAL TRIALS
A list of ongoing clinical trials is given in
Tables 1, 2 and 3.
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LEGATO-HD (NCT02215616)
Study title: A Clinical Study in Subjects With
Huntington’s Disease to Assess the Efficacy and
Safety of Three Oral Doses of Laquinimod [9].
Intervention: Laquinimod, an immunomodulatory
molecule [10].
Description: The LEGATO-HD trial aims to com-
pare the efficacy and safety of laquinimod 0.5 mg
qd, 1 mg qd, 1.5 mg qd, and placebo qd, for disease
modification in people with HD (CAG repeat num-
ber ≥ 36 plus Unified Huntington’s Disease Rating
Scale (UHDRS) Total Motor Score (TMS) >5), aged
between 21 and 55 years old.
Participant involvement will last for 12 months of
treatment. The trial is a phase 2, international, multi-
center, randomized, placebo controlled, double blind,
parallel study. The recruitment aim is 400 participants
in Canada, Czech Republic, France, Germany, India,
Israel, Italy, Netherlands, Portugal, Russia, Spain,
United Kingdom, and United States of America.
The primary outcome is change from baseline
in the UHDRS TMS after 1, 3, 6, and 12 months
of treatment. The secondary outcomes involve the
UHDRS Total Functional Capacity (TFC), the Clin-
ician’s Interview-Based Impression of Change Plus
Caregiver Input (CIBIC-Plus) global score, the
Huntington’s Disease Cognitive Assessment Battery
(HD-CAB), and caudate volume.
Sponsors/funders: Teva Branded Pharmaceutical
Products, R&D Inc.
Comments: Along the course of this study, due
to safety concerns derived from a study of laquini-
mod in multiple sclerosis, the sponsor opted to stop
the 1.5 mg qd dosage but maintain the others. This
study is now fully recruited [11] with an expected
completion date of August 2018.
IONIS-HTTRx (NCT02519036)
Study title: Safety, Tolerability, Pharmacokinetics,
and Pharmacodynamics of IONIS-HTTRx in Patients
With Early Manifest Huntington’s Disease [12]
Intervention: IONIS-HTTRx, an antisense
oligonucleotide against the huntingtin pre-messenger
RNA [13].
Description: The IONIS-HTTRx trial aims to
assess the safety, tolerability, pharmacokinetics and
pharmacodynamics of multiple ascending doses of
IONIS-HTTRx administered intrathecally, compar-
ing with intrathecal placebo, for disease modification
in people with HD, aged between 25 and 65 years old.
HTTRx is an antisense oligonucleotide targeting the
pre-mRNA transcript of the HTT gene in an allele-
nonselective manner, with the aim of reducing the
production of mutant huntingtin protein. The inter-
vention is administered 4 times at 4 week intervals
over the course of 13 weeks. The dose has ascended
consecutively throughout the study.
Each participant’s involvement will last for 29
weeks. It is a phase 1b/2a, international multi-center,
randomized, placebo controlled, double blind, par-
allel, dose-ascending study, taking place in Canada,
Germany and the United Kingdom. The recruit-
ment goal of 46 participants was reached in June
2017 [14].
The primary outcome is safety and tolerability at
29 weeks. The secondary outcomes involve phar-
macokinetic and pharmacodynamic measures in the
cerebrospinal fluid, such as peak drug concentrations,
time to peak dose concentrations, huntingtin concen-
tration, neurofilament light concentration, and also
ventricular volume and performance on the HD Cog-
nitive Assessment Battery (HD-CAB).
Sponsors/funders: Ionis Pharmaceuticals, Inc.
Comments: This trial is currently fully recruited
and an open-label extension was announced in June
2017 for the participants in the original trial.
COMPLETED CLINICAL TRIALS
Amaryllis (NCT02197130)
Study title: Randomized, Placebo Controlled Study
Of The Efficacy And Safety Of PF-02545920 In Sub-
jects With Huntington’s Disease [15].
Intervention: PF-02545920, a phosphodiesterase
10a inhibitor [16].
Description: The goal of the Amaryllis trial was
to compare the efficacy and safety of PF-02545920
5 mg bid, PF-02545920 20 mg bid, and placebo bid,
for symptomatic relief of motor impairment in peo-
ple with early HD (CAG repeat number ≥ 36 plus
UHDRS TFC ≥ 7) and chorea (UHDRS TMS ≥ 10),
aged between 30 and 65 years old.
Participant involvement lasted for 26 weeks. It
was a phase 2, international, multi-center, random-
ized, placebo controlled, double blind, parallel study
conducted in Canada, Germany, Poland, United
Kingdom, and United States of America. 272 par-
ticipants were recruited.
The primary outcome was change from baseline
in the UHDRS TMS after 26 weeks of treatment.
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The secondary outcomes involved the UHDRS TFC,
the Clinical Global Impression-Improvement, the
Columbia Suicide Severity Rating Scale (C-SSRS),
extrapyramidal symptoms, and white cell counts and
neutrophil counts.
Sponsors/funders: Pfizer
Results: The trial was completed on September
2016. Although the results have not been released
in a peer-reviewed publication, Pfizer has officially
announced that the phosphodiesterase 10a inhibitor
did not meet its goals in improving motor impairment
in people with HD. Indeed several other secondary
outcomes remained unchanged, such as functional
ability [17]. As a consequence, the ongoing 12
month-long open-label extension (NCT02342548) of
PF-02545920 20 mg bid was discontinued in Febru-
ary 2017 [18].
Pride-HD (NCT02006472)
Study title: A Phase 2, to Evaluating the Safety and
Efficacy of Pridopidine Versus Placebo for Symp-
tomatic Treatment in Patients With Huntington’s
Disease [19].
Intervention: Pridopidine, a dopaminergic stabi-
lizer [20].
Description: Pride-HD trial aimed to compare the
efficacy and safety of pridopidine 45 mg bid, 67.5 mg
bid, 90 mg bid, 112.5 mg bid, and placebo bid, for
symptomatic relief of motor impairment in people
with HD (CAG repeat number ≥ 36 plus UHDRS
Independence Score < 90%) and chorea (UHDRS
TMS ≥ 25), aged ≥ 21 years old.
It lasted for 52 weeks, was a phase 2, international,
multi-center, randomized, placebo controlled, dou-
ble blind, parallel study taking place in Australia,
Austria, Canada, Czech Republic, Denmark, France,
Germany, Italy, Netherlands, Poland, Russia, United
Kingdom, and United States of America. It recruited
408 participants.
The primary outcome was change from baseline in
the UHDRS TMS after 26 weeks of treatment. The
secondary outcomes involved the modified Physical
Performance Test, and adverse events. Early in the
course of the study, the sponsors instituted a change
in the study design, from a 26-week study focused
primarily on changes in motor symptoms as mea-
sured by the TMS, to a longer 52-week study to
explore pridopidine’s potential impact on functional
endpoints.
Sponsors/funders: Teva Branded Pharmaceutical
Products, R&D Inc., European Huntington’s Disease
Network (EHDN) and Huntington’s Study Group
(HSG).
Results: The trial was completed on July 2016. On
September 2016 Teva announced on its website that
“pridopidine demonstrates slowing of progression of
Huntington disease in Pride-HD study as measured
by total functional capacity” [21]. This announce-
ment sparked some controversy [22], since the data
presented by Teva at the 9th EHDN Plenary Meeting
2016 The Hague showed that Pride-HD failed to meet
its primary endpoint – change in UHDRS TMS at
26 weeks [21]. The interpretation of potential bene-
fit hinged upon of a lack of decline in the UHDRS
TFC at the extended 52-week timepoint. The effect
was only significant in patients taking the lowest dose
of pridopidine. The sponsor also pointed out “an
unusually high placebo effect” that complicated inter-
pretation of the findings. The Chairs of the EHDN
Executive Committee issued a statement responding
to Teva’s announcement, saying “there has been dis-
cussion over the statement in the press release that
these results indicate that pridopidine slows down
disease progression in HD. This statement needs
to be read in the context of the whole document,
which clearly speaks about slowing decline in func-
tional capacity. This should not be misunderstood
as a demonstration of disease modification or of
neuroprotection” [23].
Still, the final results of this study have not yet
been published, and we look forward to seeing them
after peer review. The open label extension of this
trial—Open PRIDE-HD (NCT02494778)—is still
ongoing, according to the latest public information.
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